Go Back

//COAs white paper// Why are they important criteria in the evaluation of dossiers by health authorities?

Diverse elements have combined in recent years to make Clinical Outcome Assessments (COAs), and particularly Patient Reported Outcomes (PROs), important criteria for various health authorities in the evaluation of new therapeutic strategies. So Olivier Chassany has written this COAs white paper in order to deal with their importance in the evaluation by health authorities.

Why is this and what are the consequences for evaluation of new drugs in clinical development programs? When should COA endpoints be considered for inclusion in a new drug development program?

By Olivier Chassany, Professor of PROs & Clinical Endpoints research at the University Paris-Diderot, France


COAs white paper health authorities


Last update : 7 December 2016


  • 22 October
    OCT Nordics - Oct 22&23 - Copenhagen, Denmark - Booth #10 - Schedule a meeting with Kayentis
  • 02 November
    ISPOR - Nov 2-6 - Copenhagen, Denmark - Schedule a meeting with Kayentis   ISPOR
  • 10 November
    DIA Japan 2019 - Nov 10-12 - Tokyo Big Sight, Ariake - Booth #42 -  Schedule a meeting with Kayentis
  • 19 November
    DMB - Nov 19 - Paris, France - Booth #14 - Schedule a meeting with Kayentis
  • Follow us

    Download our brochure